Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

NCT04444284 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: Investigational RSV vaccine MV-012-968 (Dosage 1)
BIOLOGICAL: Investigational RSV vaccine MV-012-968 (Dosage 2)
OTHER: Placebo
BIOLOGICAL: Investigational RSV vaccine MV-012-968 (Dosage 3)

Sponsor

Meissa Vaccines, Inc.